What is Recursion Pharmaceuticals, Inc. stock?

Recursion Pharmaceuticals, Inc. Business Overview

Recursion Pharmaceuticals, Inc. (RXRX) is a clinical-stage biotechnology company leading the transition from traditional trial-and-error drug discovery to a "search-and-discovery" model powered by artificial intelligence (AI). Based in Salt Lake City, Utah, Recursion integrates physical laboratory automation with massive-scale computational power to decode biology and industrialize the discovery of new medicines.

1. Core Business Segments: The Recursion OS

At the heart of the company is the Recursion Operating System (Recursion OS), a multi-layered platform designed to map and navigate trillions of biological and chemical relationships.

The Recursion Data Universe: This is one of the world's largest proprietary biological and chemical datasets. As of late 2024, it encompasses over 25 petabytes of high-dimensional data, including images of human cells (phenomics), transcriptomics, and protein-ligand interactions.
The Recursion Map: Using the BioHive-2 supercomputer (powered by NVIDIA H100 GPUs), Recursion uses generative AI and machine learning to "map" how different diseases affect cells and how potential drugs can reverse those effects. This allows the company to predict drug efficacy and toxicity before ever entering a clinical trial.
The Pipeline: Unlike many AI-only companies, Recursion maintains a robust internal pipeline. Key clinical candidates include:
• REC-994: For Cerebral Cavernous Malformation (Phase 2).
• REC-2282: For Neurofibromatosis Type 2 (Phase 2).
• REC-4881: For FAP and AXIN1/APC-mutant cancers (Phase 2).

2. Business Model Characteristics

Industrialized Discovery: Recursion operates a "wet lab" that is highly automated, capable of performing up to 2.2 million experiments per week. This provides a continuous feedback loop between physical results and AI model refinement.
Platform-as-a-Service (PaaS) and Partnerships: Beyond its own drugs, Recursion partners with pharmaceutical giants. For example, its collaboration with Roche and Genentech involves exploring up to 40 programs in neuroscience and oncology, potentially worth billions in milestones.
Acquisition of Exscientia: In late 2024, Recursion finalized its acquisition of Exscientia, integrating advanced automated medicinal chemistry and structure-based drug design into its platform, creating a "full-stack" AI drug discovery powerhouse.

3. Competitive Moats and Strategy

Data Moat: Most AI companies rely on public data. Recursion generates its own proprietary, standardized, and unbiased data, which is crucial for training high-quality machine learning models.
NVIDIA Strategic Partnership: NVIDIA invested $50 million in Recursion in 2023. This partnership grants Recursion early access to cutting-edge hardware and software (like BioNeMo), accelerating its "BioHive" supercomputing capabilities.
Vertical Integration: By controlling the process from target discovery to clinical execution, Recursion reduces the "valley of death" where most drug candidates fail.

Recursion Pharmaceuticals, Inc. Development History

Recursion’s journey reflects the evolution of "TechBio"—the intersection of deep technology and biological science.

1. Foundation and Early Exploration (2013 - 2016)

Recursion was co-founded in 2013 by Chris Gibson, Blake Borgeson, and Dean Li. The company began as a spinoff from the University of Utah. The initial goal was to use computer vision to identify how cells changed shape when treated with different drugs, focusing primarily on rare diseases where data was scarce.

2. Scaling the Platform and Series Funding (2017 - 2020)

During this stage, Recursion transitioned from a small startup to an industrial-scale operation.
• 2017-2019: The company raised significant venture capital (Series B and C), allowing them to build out their automated "wet labs."
• 2020: A pivotal year marked by a $239 million Series D round and the announcement of a massive collaboration with Bayer to find new treatments for fibrotic lung and heart diseases.

3. Public Offering and Strategic Hypergrowth (2021 - Present)

IPO (April 2021): Recursion debuted on the NASDAQ (RXRX), raising $436 million, signaling strong market interest in AI-driven biotech.
2023 NVIDIA Investment: The $50 million investment from NVIDIA served as a massive validator, pushing Recursion into the spotlight as the leader in AI-accelerated biology.
2024 Consolidation: The acquisition of Exscientia transformed the company into a leader with a combined pipeline and an end-to-end platform covering everything from target discovery to precision chemistry.

4. Analysis of Success Factors

Success Factors: Recursion’s success is attributed to its "biology-first" approach supported by technology. While others focused solely on software, Recursion built the physical infrastructure to generate the data needed to make that software useful.
Challenges: Like all biotech companies, Recursion faces the high risk of clinical trial failures. While AI can improve the probability of success, the biological complexity of human bodies remains a hurdle that technology is still learning to navigate.

Industry Overview

The AI-driven drug discovery market is a rapidly expanding segment of the global pharmaceutical industry. Traditional drug discovery takes 10-15 years and costs over $2.5 billion per drug, with a 90% failure rate. AI aims to disrupt this "Eroom’s Law" (the inverse of Moore’s Law in drug R&D).

1. Industry Trends and Catalysts

Generative AI in Biology: Similar to Large Language Models (LLMs) like GPT, "Large Biological Models" are now being used to predict protein folding and molecular interactions.
Shift to Precision Medicine: There is a growing trend toward "personalized" treatments based on genetic and cellular data, a field where AI excels.
Big Pharma Adoption: Companies like Eli Lilly, Pfizer, and Novartis are increasingly outsourcing discovery to AI firms or acquiring them to refill their patent pipelines.

2. Competitive Landscape

Recursion competes in a high-stakes environment with both specialized AI firms and traditional CROs (Contract Research Organizations).

3. Industry Status and Recursion's Position

Market Leadership: Recursion is currently considered a "top-tier" player in the TechBio space. Following the Exscientia merger, it holds one of the most diversified pipelines in the industry.
Financials (Q3 2024 Context): Recursion maintains a strong cash position (typically exceeding $400M+ post-merger) to fund operations into 2027. While not yet profitable—typical for clinical-stage biotechs—its revenue is driven by milestone payments from Bayer, Roche, and NVIDIA.
Future Outlook: The industry is moving from the "hype" phase into the "proof" phase. The next 12-24 months are critical for Recursion as Phase 2 clinical data for its lead candidates will determine if its AI-first approach can truly outperform traditional methods in a clinical setting.

Recursion Pharmaceuticals, Inc. (RXRX) Financial Health Rating

The financial health of Recursion Pharmaceuticals reflects its status as a high-growth, high-burn "TechBio" company. While it maintains a robust cash position through strategic partnerships and equity raises, it remains pre-revenue in terms of product sales, relying on milestone payments from giants like NVIDIA, Roche, and Sanofi.

Note: Scores are based on comparison within the biotechnology sector and recent SEC filings as of February 2026.

Recursion Pharmaceuticals, Inc. Development Potential

Strategic Roadmap and Major Events

Recursion is transitioning from a platform-discovery phase to a clinical validation phase. The most significant recent milestone is the successful business combination with Exscientia (completed in late 2024), which added automated chemistry synthesis to Recursion's biological data platform, creating a "full-stack" drug discovery engine.

Catalysts for New Business and Innovation

1. NVIDIA Collaboration & BioHive-2: Recursion completed the BioHive-2 supercomputer in mid-2024, powered by NVIDIA H100 GPUs. This makes it one of the most powerful AI training environments in biopharma, enabling the release of biological foundation models like Phenom-1 to the broader industry via NVIDIA BioNeMo.
2. High-Value Clinical Readouts: Key upcoming data includes Phase 2 readouts for REC-4881 (targeting FAP) and REC-1245 (oncology), which serve as the first "proof of concept" for AI-designed molecules.
3. Partnership Maturation: The company has received cumulative upfronts and milestones exceeding $500M. In February 2026, it achieved its 5th milestone with Sanofi, highlighting the consistent value generation of its AI-native operating system (Recursion OS).

Market Positioning: TechBio Leadership

Recursion is uniquely positioned at the intersection of tech and biology. Unlike traditional biotechs, Recursion focuses on industrializing discovery. It currently synthesizes 90% fewer compounds than industry benchmarks to find a lead candidate, potentially cutting discovery timelines from 40 months to just 17 months.

Recursion Pharmaceuticals, Inc. Pros and Risks

Company Pros (Upside Factors)

• Exceptional Cash Runway: With $754M in cash, the company is funded into 2028, a rare stability in the volatile biotech sector.
• NVIDIA Partnership: Direct technical and strategic backing from NVIDIA provides a "halo effect" and access to cutting-edge compute resources that competitors cannot match.
• Large-Scale Data Advantage: Owns a proprietary dataset exceeding 25 petabytes, allowing for AI training on real-world biological reactions rather than public, noisy data.
• Diverse Revenue Streams: Not solely dependent on its own drugs; earns significant income from collaboration milestones with Roche/Genentech, Bayer, and Sanofi.

Potential Risks (Downside Factors)

• High Cash Burn: Annual losses are substantial (over $600M in FY 2025). Any delay in milestone payments or clinical failure could accelerate the need for dilutive equity raises.
• Clinical Discontinuations: In May 2025, the company discontinued three programs (REC-994, REC-2282, REC-3964) following a strategic review. This highlights the inherent high-risk nature of drug development, regardless of AI efficiency.
• NVIDIA Equity Exit: Recent filings indicate NVIDIA has exited its direct equity position in RXRX. While technical collaboration continues, the loss of a major "anchor" shareholder has weighed on market sentiment.
• Regulatory Uncertainty: The FDA’s pathway for AI-designed drugs is still evolving. Regulatory hurdles for "black box" AI discoveries could lead to longer approval times.

How Do Analysts View Recursion Pharmaceuticals, Inc. and RXRX Stock?

As of early 2026, analyst sentiment toward Recursion Pharmaceuticals (RXRX) reflects a cautious yet optimistic outlook on the intersection of artificial intelligence and drug discovery. Often referred to as a "TechBio" pioneer, Recursion is viewed by Wall Street as a high-risk, high-reward play that is transitioning from a conceptual AI platform to a clinical-stage powerhouse. Following the full integration of its landmark acquisition of Exscientia in 2025, analysts are closely monitoring the company's ability to shorten drug development timelines.

1. Institutional Perspectives on Core Strategy

The "Industrialization" of Drug Discovery: Major investment banks, including Goldman Sachs and J.P. Morgan, have highlighted Recursion’s unique approach to "mapping" biology. Analysts believe the company’s RecursionOS, powered by its BioHive-2 supercomputer (one of the most powerful in the world), gives it a competitive edge in screening billions of chemical-biological combinations that traditional labs cannot match.

Validation Through High-Value Partnerships: A key pillar of the bull case is Recursion's extensive collaboration network. Analysts point to the deep integration with NVIDIA (which invested $50 million in the company) and long-term R&D partnerships with Roche and Bayer as external validation of the company's technology. Specifically, the expansion of the Roche collaboration into oncology and neuroscience is seen as a multi-billion dollar milestone opportunity.

Synergy from Exscientia Merger: Analysts from Needham & Company have noted that the merger with Exscientia has created a "full-stack" leader in AI-driven drug discovery, combining Recursion’s automated "wet lab" biology with Exscientia’s world-class automated chemistry capabilities. This is expected to significantly reduce the cost of bringing candidates to Phase 1 trials.

2. Stock Ratings and Price Targets

Market consensus for RXRX remains lean toward a "Moderate Buy" or "Overweight" rating as of Q1 2026:

Rating Distribution: Out of approximately 12 analysts covering the stock, roughly 65% maintain a "Buy" or equivalent rating, while 35% recommend a "Hold." Sell ratings remain rare, reflecting general confidence in the long-term trend of AI in healthcare.

Target Price Estimates:
Average Target Price: Consensus estimates hover around $14.50 to $16.00, representing a potential upside of approximately 40-60% from mid-2025 trading levels.
Optimistic Outlook: Top-tier bulls, such as KeyBanc, have set price targets as high as $22.00, citing the potential for "unprecedented efficiency" in the company's internal pipeline for rare diseases and oncology.
Conservative Outlook: More cautious analysts, such as those at Morgan Stanley, have maintained a price target closer to $9.00, arguing that the true value of the AI platform won't be proven until a major candidate successfully clears Phase 2 or Phase 3 clinical trials.

3. Key Risk Factors and "Bear" Arguments

Despite the technological enthusiasm, analysts warn of several headwinds:

The "Binary" Risk of Clinical Trials: Analysts emphasize that while AI can find candidates faster, biology remains unpredictable. The recent mixed results from early-stage trials (such as the REC-994 program for CCM) serve as a reminder that AI-designed drugs face the same regulatory hurdles and biological complexities as traditional drugs.

Cash Burn and Dilution: As of the latest 2025 filings, Recursion maintains a healthy cash runway (often cited as reaching into 2027), but analysts are wary of the high operational costs associated with running a massive supercomputing infrastructure alongside clinical trials. Future capital raises could lead to shareholder dilution if milestones are delayed.

Execution Risk in Integration: Some analysts remain skeptical about the speed of integrating Exscientia’s operations, noting that merging two distinct AI platforms and corporate cultures can lead to short-term disruptions in R&D velocity.

Summary

The Wall Street consensus is that Recursion Pharmaceuticals is the "Standard Bearer" for AI in Biotech. While the stock remains volatile and sensitive to broader biotech sector trends, analysts believe that if Recursion can demonstrate even a slight improvement in the clinical success rate of its 20+ pipeline programs, it could redefine the valuation metrics for the entire pharmaceutical industry. For most analysts, RXRX is viewed as a foundational holding for investors looking to gain exposure to the digital transformation of medicine.

Recursion Pharmaceuticals, Inc. (RXRX) Frequently Asked Questions

What are the key investment highlights for Recursion Pharmaceuticals (RXRX), and who are its main competitors?

Recursion Pharmaceuticals is a leader in the "TechBio" space, utilizing its RecursionOS platform—a combination of automated wet-lab biology and dry-lab machine learning—to industrialize drug discovery. A major highlight is its strategic partnership with NVIDIA, which includes a $50 million investment and access to high-performance computing to train its "BioHive-2" supercomputer. Additionally, the company has significant collaborations with Roche/Genentech and Bayer.
Main competitors include other AI-driven drug discovery firms such as Schrödinger (SDGR), Exscientia (EXAI), and AbCellera (ABCL), as well as traditional pharmaceutical giants developing internal AI capabilities.

Is the latest financial data for RXRX healthy? What are the revenue, net profit, and debt levels?

According to the Q3 2024 earnings report (ended September 30, 2024), Recursion reported revenue of $21.1 million, up from $10.5 million in the same period last year, primarily driven by collaboration milestones. However, like most clinical-stage biotech firms, it is not yet profitable, reporting a net loss of $95.8 million for the quarter.
The company maintains a strong liquidity position with $430.1 million in cash and cash equivalents. Its debt levels remain manageable as it focuses on equity-based funding and strategic partnerships to fuel its high R&D burn rate.

Is the current RXRX stock valuation high? How do its P/E and P/S ratios compare to the industry?

Since Recursion is currently pre-profit, the Price-to-Earnings (P/E) ratio is not a meaningful metric. Investors typically look at the Price-to-Sales (P/S) ratio. As of late 2024, RXRX trades at a high P/S multiple (often exceeding 20x), which is significantly higher than the average for the broader healthcare sector but common for high-growth AI-biotech firms.
Valuation is largely driven by the "optionality" of its massive data library and the success of its Phase 2 clinical pipeline rather than current revenue.

How has the RXRX stock price performed over the past year compared to its peers?

Over the past 12 months, RXRX has experienced significant volatility. While it saw a massive surge in mid-2023 following the NVIDIA announcement, the stock has faced pressure in 2024 due to a general "risk-off" sentiment in the biotech sector and the dilution from its acquisition of Exscientia.
Compared to the XBI (SPDR S&P Biotech ETF), RXRX has shown higher beta, meaning it tends to outperform during AI-driven rallies but underperform during periods of high interest rates or clinical trial setbacks.

Are there any recent industry tailwinds or headwinds affecting RXRX?

Tailwinds: The rapid advancement of Generative AI and Large Language Models (LLMs) for biology (like AlphaFold 3) has increased institutional interest in Recursion's data-first approach. The acquisition of Exscientia in 2024 is also seen as a major move to consolidate the AI-drug discovery market.
Headwinds: The primary headwind remains the "clinical gap"—the time it takes to prove that AI-designed drugs actually succeed in human trials at a higher rate than traditional methods. High interest rates also generally weigh on valuations of pre-revenue biotech companies.

Have any major institutions recently bought or sold RXRX stock?

Recursion has strong institutional backing. ARK Investment Management (Cathie Wood) is a prominent long-term holder, frequently adding to positions during dips. NVIDIA Corporation remains a strategic stakeholder. According to recent 13F filings, institutional ownership remains high at approximately 60-65%, though some hedge funds have rotated out of the position to manage volatility. Baillie Gifford and Vanguard also hold significant positions as of the latest reporting cycle.